Improving patient access to life-enhancing medications
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals.
We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

We offer patients better, safer & more accessible medicines.
For investors
Company AnnouncementsFor investors


Mayne Pharma 2023 Half Year Results Media Release
28 Feb 2023
Mayne Pharma’s CEO, Mr Shawn O'Brien said, “The performance of our business during the first half of FY23 is categorized by building momentum in our Branded Products Division."
Learn more


Mayne Pharma announces sale of U.S. Generics Portfolio to Dr. Reddy’s
27 Feb 2023
Mayne Pharma’s CEO Mr. Shawn Patrick O’Brien said: “Divesting the retail generics portfolio is an important step forward for the Company as we continue to rationalise our portfolio. With this transaction, we free up working capital, allowing us to more exclusively focus resources on core areas of value for business growth, namely our branded verticals in US women's health and dermatology."
Learn more


Mayne Pharma signs exclusive license agreement for three women’s health products and a range of prenatal vitamins in the US
5 Dec 2022
Mayne Pharma Group Limited has signed an exclusive license agreement with TherapeuticsMD, Inc. a NASDAQ listed company for three branded women’s health products and a portfolio of prenatal vitamins in the US (License Agreement)
Learn more


Mayne Pharma to return up to $113m to shareholders
28 Oct 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that following completion of the sale of Metrics Contract Services (Metrics) it intends to return up to $113 million to shareholders, through a combination of cash distributions.
Learn more


Mayne Pharma completes sale of Metrics Contract Services
4 Oct 2022
Mayne Pharma Group Limited is pleased to announce the completion of the sale of Metrics Contract Services (Metrics) to Catalent Pharma Solutions, Inc. for US$475 million (approximately A$722 million at current exchange rates).
Learn more


Mayne Pharma appoints new CEO
28 Sep 2022
Mayne Pharma Group Limited is pleased to announce it has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer and Managing Director effective 1 October 2022. This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.
Learn more